Investigation shows suPAR relates to cardiovascular calcification and outcomes in peritoneal dialysis patients, implying potential health risks.
Objective Cardiovascular calcification (CVC) is an important factor influencing cardiovascular outcomes in peritoneal dialysis (PD). We investigated the association of serum soluble urokinase plasminogen activator receptor (suPAR) with CVC progression and cardiovascular outcomes in PD patients.
No takes yet. Share an insight, caveat, or question.
Guan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: